Abstract 99P
Background
Patients with chemotherapy-responsive advanced biliary tract cancer (BTC) are usually observed post 6 months of gemcitabine-based therapy, though most progress within a short time-span and there is limited prospective evidence for maintenance strategies.
Methods
The study is an integrated phase II – III randomised clinical trial (Clinical Trial Registry of India number: CTRI/2017/10/010112) conducted at 2 centres in India. Eligible patients with advanced BTC who had responsive or stable disease status post 6 months of gemcitabine – based chemotherapy were randomly assigned (1:1) to either observation arm (O) or intervention arm (BEER), which was a combination of Bevacizumab 5 mg/m2 IV every 21 days plus erlotinib 100 mg once daily, . Both arms were continued till disease progression, significant toxicity or patients choice. The primary endpoint of the phase II component was progression free survival, measured from randomization into the trial.
Results
Between May 2021 and November 2022, 98 patients (O: 48; BEER: 50) comprising 78 patients with gallbladder cancer (GBC) and 20 patients with cholangiocarcinoma (CC) were randomised with all 98 patients included in the final analysis. With a median follow up of 11.2 months, patients in the BEER cohort showed an improved PFS compared to the observation cohort [5.2 months (95% CI: 3.4-6.9) vs. 3 months (95% CI: 2.5 - 3.5); p=0.004]. The CC cohort tended to derive greater benefit from BEER (6.7 months vs. 2.2 months) than the GBC cohort (4.3 months vs. 3 months). There were no grade 3 or grade 4 adverse events noted, though temporary cessation of erlotinib was required due to grade 2 skin rash in 7 patients (14%), and grade 2 oral stomatitis in 1 patient (2%).
Conclusions
The combination of bevacizumab and erlotinib improves progression free survival in patients with chemotherapy responsive advanced BTC in this phase 2 clinical trial. The ongoing phase III component of the study will evaluate whether the significant benefit in PFS translates to improvement in overall survival.
Clinical trial identification
CTRI/2017/10/010112.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cadilla Pharma Pvt Ltd (supported bevacizumab) Dr. Reddy's Lab pvt Ltd (supported bevacizumab) LUPIN Pharma pvt Ltd Intas pvt Ltd.
Disclosure
A. Ramaswamy: Financial Interests, Institutional, Research Grant: Cipla Health Limited, Dr Reddy Laboratories, Zydus Lifesciences. V.S. Ostwal: Financial Interests, Institutional, Funding, IIS: Cadilla Pharmaceuticals pvt Lts, Reddy's pvt Ltd, Lupin, BDR; Financial Interests, Personal, Invited Speaker, GI ESMO 22: AstraZeneca; Financial Interests, Institutional, Advisory Board: Mankind, Natco. All other authors have declared no conflicts of interest.
Resources from the same session
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17
126P - Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
Presenter: Adelaida Lacasta
Session: Poster session 17